CureVac Current Ratio 2021-2021 | CVAC

CureVac current ratio from 2021 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CureVac Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-12-31 $1.06B $0.40B 2.63
2021-09-30 $1.72B $0.96B 1.79
2020-12-31 $1.59B $0.28B 5.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.505B $0.116B
CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00